Shenzhen University Publishes Paper on Ultra-Early Cancer Detection Tech in Optica Journal

Shenzhen University's Groundbreaking Publication in Optica Journal

Shenzhen University has made headlines with a pioneering research paper published in the prestigious Optica journal, introducing an ultra-sensitive light-based sensor for early cancer detection. This innovation from the College of Physics and Optoelectronic Engineering promises to revolutionize how we identify cancer at its molecular inception, long before tumors become visible on imaging scans. Led by Distinguished Professor Han Zhang, the study demonstrates detection capabilities at sub-attomolar levels—equivalent to spotting just a handful of molecules in a blood sample.

The paper, titled "Sub-Attomolar-Level Biosensing of Cancer Biomarkers Using SHG Modulation in DNA Programmable Quantum Dots/MoS₂ Disordered Metasurfaces," showcases the integration of nanotechnology, CRISPR technology, and nonlinear optics. This achievement underscores Shenzhen University's rising stature in global biomedical research, particularly in photonics and biophotonics.

Han Zhang: Visionary Leader Behind the Innovation

Professor Han Zhang, a Fellow of the Optical Society of America and Director of Shenzhen University's College of Physics and Optoelectronic Engineering, spearheads this research. With expertise in optics, lasers, biophotonics, and two-dimensional materials like black phosphorus, Zhang has amassed thousands of citations on Google Scholar. Appointed Distinguished Professor in 2013, his work bridges materials science and biomedical applications, positioning SZU as a hub for cutting-edge optical technologies.

"Our sensor combines nanostructures made of DNA with quantum dots and CRISPR gene editing technology," Zhang explained, highlighting the programmable nature of DNA as building blocks for precise sensor assembly. This interdisciplinary approach exemplifies how Chinese universities are fostering talent in higher education research.Explore research positions at institutions like SZU.

The Critical Challenge of Early Cancer Detection

Cancer remains a leading cause of mortality worldwide, with lung cancer particularly deadly due to late-stage diagnosis. Traditional methods like CT scans detect tumors only after significant growth, missing the ultra-early phase where intervention yields the highest survival rates. Biomarkers such as microRNA-21 (miR-21)—short, non-coding RNAs overexpressed in lung cancer cells—offer promise but exist at femtogram levels in blood, challenging conventional detection.

In China, where lung cancer incidence is high due to smoking and pollution, early screening is vital. SZU's technology addresses this by enabling simple blood tests, potentially shifting paradigms in oncology.

Decoding the Technology: From DNA Nanostructures to SHG Detection

At its core, the sensor leverages second harmonic generation (SHG), a nonlinear optical phenomenon where incoming light at frequency ω produces output at 2ω. Here's how it works step-by-step:

• Assembly: DNA tetrahedrons—self-folding pyramid-shaped nanostructures—precisely position semiconductor quantum dots (QDs) nanometers from a molybdenum disulfide (MoS₂) metasurface, enhancing local optical fields for amplified SHG signals.
• CRISPR Activation: CRISPR-Cas12a, programmed with a guide RNA specific to miR-21, binds the target biomarker.
• Trans-Cleavage: Upon binding, Cas12a indiscriminately cleaves nearby single-stranded DNA linkers holding QDs in place.
• Signal Change: Detached QDs cause a sharp drop in SHG intensity, detectable without amplification due to low background noise.

This process, fully detailed in the Optica paper, achieves detection limits of 1.6 × 10⁻¹⁸ M for miR-21.

Impressive Performance in Lab and Real-World Samples

Tested rigorously, the sensor distinguished miR-21 from similar RNAs with near-perfect specificity. In human serum from lung cancer patients, it reliably quantified biomarker levels, outperforming fluorescence-based methods limited by quenching and diffusion. Quantitative analysis showed linear response across seven orders of magnitude, from sub-attomolar to nanomolar concentrations.

Such metrics position this as a leap forward for point-of-care diagnostics.Read the full Optica release.

Shenzhen University: A Rising Star in Chinese Higher Education

Founded in 1983, Shenzhen University embodies China's innovative spirit, mirroring the city's tech boom. Ranked 45th in China and 598th globally by EduRank, SZU excels in optics (top in Guangdong) and oncology research per Nature Index. With 302 National Natural Science Foundation projects in recent years (23rd nationally), it invests heavily in interdisciplinary labs.

The College of Physics and Optoelectronic Engineering, under Zhang's leadership, drives photonics breakthroughs, attracting global talent. For academics eyeing opportunities in China, explore SZU-like institutions via our higher ed resources.

Placing the Innovation in China's Oncology Research Landscape

China leads in early cancer detection tech, from AI-powered pancreatic screening at Alibaba DAMO Academy to CTC platforms at CityUHK. SZU's optical sensor complements these, offering label-free, amplification-free detection. miR-21's role as a biomarker is well-established, with prior studies confirming its elevation in early lung adenocarcinoma.

This publication elevates SZU amid peers like Fudan and Shanghai Jiao Tong in oncology rankings, highlighting Guangdong's research prowess.

Potential Impacts: From Personalized Medicine to Global Health

Ultra-early detection could boost 5-year survival from 20% (late-stage lung cancer) to over 90%. In China, with 800,000+ annual lung cancer cases, routine blood screenings via portable devices could save millions. Zhang envisions daily monitoring for at-risk groups and adaptation for Alzheimer's or viruses.

• Cost reduction: No complex imaging needed.
• Accessibility: Portable for rural clinics.
• Personalization: Track treatment response via miR-21 dynamics.

Stakeholders, including oncologists, praise its potential to lower healthcare burdens.

Future Directions and Challenges Ahead

Next steps include multiplexing for multi-biomarker panels and clinical trials. Challenges like sensor stability in diverse sera and regulatory approval remain, but SZU's momentum—evident in 2023's Top 10 Advances—suggests rapid progress.

Integration with AI for data analysis could further enhance accuracy. Aspiring researchers can find roles in biophotonics.

Why This Matters for Higher Education in China

This Optica paper exemplifies China's push for research excellence, with universities like SZU securing top journal spots. It attracts international collaborations, bolstering academic careers. As China invests in biomed, SZU sets benchmarks for innovation-driven higher ed.

Conclusion: A Beacon for Cancer Research

Shenzhen University's ultra-early cancer detection technology heralds a new era. By merging optics, nano, and biotech, it offers hope for millions. Stay informed on higher ed breakthroughs and explore opportunities at AcademicJobs.com/higher-ed-jobs, rate professors, or seek university jobs in China.